Skip to content

Clinical, Epidemiologic, and Therapeutic Characterization of Pediatric Psoriasis in the Costa Rican Social Security System

Epidemiological and Therapeutic Characterization Study of Psoriatic Disease in Patients Under 18 Years of Age at the Costa Rican Social Security (2018-2025)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07451626
Enrollment
300
Registered
2026-03-05
Start date
2026-05-01
Completion date
2027-05-01
Last updated
2026-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Psoriasis

Keywords

Costa Rica, Epidemiology, Pediatric, Psoriasis, Real-Word

Brief summary

The goal of this retrospective observational study is to characterize the clinical features, severity, comorbidities, and treatment patterns of pediatric psoriasis in patients managed in the Costa Rican Social Security System. The main questions it aims to answer are: What are the demographic and clinical characteristics of pediatric psoriasis in Costa Rica? What disease severity profiles, comorbidities, and treatments are observed in routine care? All patients \<18 years with confirmed psoriasis evaluated during the study period will be included. Data will be obtained from electronic health records without intervention or modification of treatment.

Detailed description

Pediatric psoriasis is a chronic immune-mediated inflammatory dermatosis associated with physical, psychosocial, and metabolic comorbidity burden beginning early in life. Epidemiologic and clinical data in Latin American pediatric populations remain limited, particularly in real-world care settings. This study is a retrospective observational characterization of pediatric psoriasis patients managed in the Costa Rican Social Security System. Unlike interventional trials or biologic-specific registries, it analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI or pediatric indices), comorbidities, and treatment patterns in routine practice. No therapeutic interventions or standardized follow-up are introduced. By capturing real-world pediatric psoriasis presentation and management in Costa Rica, the study provides baseline national evidence distinct from drug-specific or prospective therapeutic studies.

Interventions

None listed

Sponsors

Caja Costarricense de Seguro Social
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* Patients younger than 18 years at the time of psoriasis diagnosis. * Clinical diagnosis of psoriasis established by a specialist physician (dermatologist or trained pediatrician) or by a general practitioner within the Costa Rican Social Security System (CCSS). * Patients evaluated in CCSS healthcare facilities between January 2018 and December 2025. * Clinical records containing sufficient information on key epidemiologic and therapeutic variables relevant to the study (age, sex, date of diagnosis, clinical subtype, and treatment received).

Exclusion criteria

* Patients aged 18 years or older at the time of psoriasis diagnosis. * Clinical records incomplete or lacking sufficient information for analysis of the main study variables. * Patients with uncertain or unconfirmed diagnosis of psoriasis.

Design outcomes

Primary

MeasureTime frame
Treatment patterns used in pediatric psoriasis in real-world clinical practice (topical, phototherapy, systemic, biologic).January 2018- December 2025
Clinical and severity characteristics of pediatric psoriasis, including subtype and severity indices (e.g., PASI/BSA/DLQI or pediatric-adapted measures) documented in routine care.January 2018- December 2025
Comorbidity profile in pediatric psoriasis (e.g., metabolic, cardiovascular risk factors, psoriatic arthritis).January 2018- December 2025

Countries

Costa Rica

Contacts

CONTACTDaniel E Barquero-Orias, Dermatologist
debarque@ccss.sa.cr+506 83411026

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 8, 2026